Physician profile
Thomas A Scott
NPI 1043247430
$61,245.24
in general payments reported to CMS, 2019-2025
27 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $9,504 · 2021: $18K · 2022: $525 · 2023: $1,145 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $975 · Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $975.00 |
| Food and Beverage | $330.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32,314.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $23,932.50 | 2019-2023 | Nucala |
| Astrazeneca Pharmaceuticals LP | $2,295.48 | 2019-2025 | |
| Pfizer INC. | $371.18 | 2019-2022 | |
| Celgene Corporation | $272.75 | 2019 | |
| Optinose US, INC. | $253.89 | 2019-2022 | |
| Alk-Abello, INC | $253.33 | 2022 | |
| Genzyme Corporation | $187.38 | 2019-2025 | |
| Csl Behring | $186.27 | 2020-2021 | |
| Genentech USA, INC. | $158.30 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.36 | 2019-2021 | |
| Kaleo, INC. | $135.07 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $127.67 | 2019-2021 | |
| Dexcom, INC. | $118.08 | 2023 | Dexcom G7 Gss (161) |
| Octapharma USA, INC. | $100.63 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $65.23 | 2019-2023 | Xolair, Vabysmo |
| Novartis Pharmaceuticals Corporation | $60.43 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.26 | 2020-2022 | |
| Blueprint Medicines Corporation | $42.69 | 2021 | |
| Merck Sharp & Dohme LLC | $33.92 | 2019 | |
| Shire North American Group INC | $33.54 | 2019 | |
| Biocryst US Sales Co., LLC | $26.49 | 2021 | |
| Aytu Biopharma, INC. | $25.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $23.33 | 2020 | |
| Abbvie INC. | $13.95 | 2023 | Rinvoq |
| Sunovion Pharmaceuticals INC. | $12.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.